Simvastatin is associated with an increased risk for myopathy and rhabdomyolysis and the presence of the SLCO1B gene further increases the risk for muscle toxicity. New simvastatin dosing recommendations are provided if genotype information is available. How knowledgeable are you about the use of genotyping for medication dosing?

Please see the guideline published in Clinical Pharmacology & Therapeutics for more information.